{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:18:26Z","timestamp":1791299906751,"version":"4.1.0"},"reference-count":196,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005199","name":"Chinese Medicine Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2021ZZ001"],"award-info":[{"award-number":["2021ZZ001"]}],"id":[{"id":"10.13039\/501100005199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003853"],"award-info":[{"award-number":["82003853"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ20H310005"],"award-info":[{"award-number":["LQ20H310005"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LYY21H310009"],"award-info":[{"award-number":["LYY21H310009"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bcp.2023.115956","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T21:02:11Z","timestamp":1701550931000},"page":"115956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Role of sodium taurocholate cotransporting polypeptide (NTCP) in HBV-induced hepatitis: Opportunities for developing novel therapeutics"],"prefix":"10.1016","volume":"219","author":[{"given":"Zhentao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5195-7369","authenticated-orcid":false,"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9963","key":"10.1016\/j.bcp.2023.115956_b0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"Mortality","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bcp.2023.115956_b0010","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2215\/CJN.09180816","article-title":"Viral-associated GN: Hepatitis B and other viral infections","volume":"12","author":"Kupin","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115956_b0015","first-page":"796","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet","volume":"7","author":"Collaborators","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115956_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061486","article-title":"Hepatitis B Virus Entry into Cells","volume":"9","author":"Herrscher","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2023.115956_b0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virol.2016.06.024","article-title":"Cellular uptake of hepatitis B virus envelope L particles is independent of sodium taurocholate cotransporting polypeptide, but dependent on heparan sulfate proteoglycan","volume":"497","author":"Somiya","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2023.115956_b0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coviro.2018.04.004","article-title":"Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections","volume":"30","author":"Tu","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.bcp.2023.115956_b0035","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"3","author":"Yan","year":"2012","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.bcp.2023.115956_b0040","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1177\/24725552211017500","article-title":"Functional and pharmacological comparison of human and mouse Na(+)\/taurocholate cotransporting polypeptide (NTCP)","volume":"26","author":"Floerl","year":"2021","journal-title":"SLAS Discov"},{"issue":"39","key":"10.1016\/j.bcp.2023.115956_b0045","doi-asserted-by":"crossref","first-page":"e17305","DOI":"10.1097\/MD.0000000000017305","article-title":"Clinical and histopathologic features of sodium taurocholate cotransporting polypeptide deficiency in pediatric patients","volume":"98","author":"Dong","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11307-019-01373-y","article-title":"Role of sodium taurocholate cotransporting polypeptide as a new reporter and drug-screening platform: implications for preventing hepatitis B virus infections","volume":"22","author":"Wu","year":"2020","journal-title":"Mol. Imag. Biol."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2023.115956_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1008152729133","article-title":"Stable expression and functional characterization of a Na+-taurocholate cotransporting green fluorescent protein in human hepatoblastoma HepG2 cells","volume":"34","author":"Kullak-Ublick","year":"2000","journal-title":"Cytotechnology"},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1006\/bbrc.1998.9974","article-title":"Identification of thyroid hormone transporters","volume":"254","author":"Friesema","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6037","key":"10.1016\/j.bcp.2023.115956_b0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/317489a0","article-title":"The hepatitis B virus","volume":"317","author":"Tiollais","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115956_b0070","doi-asserted-by":"crossref","unstructured":"C. Lauber, S. Seitz, S. Mattei, A. Suh, J. Beck, J. Herstein, J. Borold, W. Salzburger, L. Kaderali, J.A.G. Briggs, R. Bartenschlager, Deciphering the origin and evolution of hepatitis B viruses by means of a family of non-enveloped fish viruses, Cell Host Microbe 22(3) (2017) 387-399 e6.","DOI":"10.1016\/j.chom.2017.07.019"},{"key":"10.1016\/j.bcp.2023.115956_b0075","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2005.03.090","article-title":"Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes","volume":"129","author":"Glebe","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0085","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1006\/viro.1996.0209","article-title":"Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity","volume":"218","author":"Bruss","year":"1996","journal-title":"Virology"},{"issue":"39","key":"10.1016\/j.bcp.2023.115956_b0090","doi-asserted-by":"crossref","first-page":"36613","DOI":"10.1074\/jbc.M102377200","article-title":"Cloning and expression of a novel hepatitis B virus-binding protein from HepG2 cells","volume":"276","author":"De Falco","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0095","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1006\/viro.1995.0002","article-title":"Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity","volume":"213","author":"Gripon","year":"1995","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jinf.2021.12.025","article-title":"Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients: Anti-HBV PreS1 antibody","volume":"84","author":"Hatooka","year":"2022","journal-title":"J. Infect."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0105","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/jvi.61.5.1672-1677.1987","article-title":"The preS1 protein of hepatitis B virus is acylated at its amino terminus with myristic acid","volume":"61","author":"Persing","year":"1987","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.bcp.2023.115956_b0110","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","article-title":"Bile acid transporters","volume":"50","author":"Dawson","year":"2009","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0115","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1172\/JCI117091","article-title":"Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+\/bile acid cotransporter","volume":"93","author":"Hagenbuch","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0120","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01432-18","article-title":"A single adaptive mutation in sodium taurocholate cotransporting polypeptide induced by hepadnaviruses determines virus species specificity","volume":"93","author":"Takeuchi","year":"2019","journal-title":"J. Virol."},{"issue":"Database issue","key":"10.1016\/j.bcp.2023.115956_b0125","first-page":"D36","article-title":"GenBank","volume":"41","author":"Benson","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"7916","key":"10.1016\/j.bcp.2023.115956_b0130","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41586-022-04857-0","article-title":"Structural insights into the HBV receptor and bile acid transporter NTCP","volume":"606","author":"Park","year":"2022","journal-title":"Nature"},{"issue":"7916","key":"10.1016\/j.bcp.2023.115956_b0135","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41586-022-04723-z","article-title":"Structural basis of sodium-dependent bile salt uptake into the liver","volume":"606","author":"Goutam","year":"2022","journal-title":"Nature"},{"issue":"7916","key":"10.1016\/j.bcp.2023.115956_b0140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41586-022-04845-4","article-title":"Structure of the bile acid transporter and HBV receptor NTCP","volume":"606","author":"Asami","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115956_b0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijid.2019.01.038","article-title":"NTCP S267F variant associates with decreased susceptibility to HBV and HDV infection and decelerated progression of related liver diseases","volume":"80","author":"Binh","year":"2019","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0150","doi-asserted-by":"crossref","first-page":"17634","DOI":"10.1038\/s41598-017-17959-x","article-title":"Effect of S267F variant of NTCP on the patients with chronic hepatitis B","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2023.115956_b0155","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1128\/JVI.03478-13","article-title":"Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide","volume":"88","author":"Yan","year":"2014","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115956_b0160","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1002\/jps.23582","article-title":"Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP\/Ntcp) and its modulation in cultured hepatocytes","volume":"102","author":"Qiu","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2023.115956_b0165","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1053\/gast.2002.33617","article-title":"Transporter-mediated bile acid uptake causes Ca2+-dependent cell death in rat pancreatic acinar cells","volume":"122","author":"Kim","year":"2002","journal-title":"Gastroenterology"},{"issue":"23","key":"10.1016\/j.bcp.2023.115956_b0170","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.88.23.10629","article-title":"Functional expression cloning and characterization of the hepatocyte Na+\/bile acid cotransport system","volume":"88","author":"Hagenbuch","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2023.115956_b0175","first-page":"S4","article-title":"\u201cLet there be bile\u201d\u2013understanding hepatic injury in cholestasis","volume":"43","author":"Sokol","year":"2006","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"7","key":"10.1016\/j.bcp.2023.115956_b0180","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gut.2004.053850","article-title":"Apoptosis: a mechanism of acute and chronic liver injury","volume":"54","author":"Guicciardi","year":"2005","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0185","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/jhep.2001.22646","article-title":"Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases","volume":"33","author":"Zollner","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0190","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.1038\/s41598-017-07012-2","article-title":"Homozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"issue":"63","key":"10.1016\/j.bcp.2023.115956_b0195","doi-asserted-by":"crossref","first-page":"106598","DOI":"10.18632\/oncotarget.22503","article-title":"Sodium taurocholate cotransporting polypeptide (NTCP) deficiency: Identification of a novel SLC10A1 mutation in two unrelated infants presenting with neonatal indirect hyperbilirubinemia and remarkable hypercholanemia","volume":"8","author":"Qiu","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0200","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.3892\/etm.2016.3752","article-title":"Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency","volume":"12","author":"Deng","year":"2016","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0205","first-page":"350","article-title":"Sodium taurocholate cotransporting polypeptide deficiency manifesting as cholestatic jaundice in early infancy: a complicated case study","volume":"19","author":"Song","year":"2017","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0210","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10545-017-0031-9","article-title":"NTCP deficiency and persistently raised bile salts: an adult case","volume":"40","author":"Van Herpe","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1620\/tjem.248.57","article-title":"Intrahepatic cholestasis of pregnancy as a clinical manifestation of sodium-taurocholate cotransporting polypeptide deficiency","volume":"248","author":"Chen","year":"2019","journal-title":"Tohoku J. Exp. Med."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0220","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0225","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","article-title":"The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention","volume":"70","author":"Liu","year":"2019","journal-title":"J. Hepatol."},{"issue":"34","key":"10.1016\/j.bcp.2023.115956_b0230","doi-asserted-by":"crossref","first-page":"56041","DOI":"10.18632\/oncotarget.10241","article-title":"Down-regulation of NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical significance","volume":"8","author":"Kang","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0235","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1478-3231.2005.01033.x","article-title":"Hepatobiliary transporter expression in human hepatocellular carcinoma","volume":"25","author":"Zollner","year":"2005","journal-title":"Liver Int."},{"issue":"9","key":"10.1016\/j.bcp.2023.115956_b0240","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1136\/gutjnl-2015-310686","article-title":"The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B","volume":"65","author":"Hu","year":"2016","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101824","article-title":"Sodium taurocholate co-transporting polypeptide deficiency","volume":"46","author":"Schneider","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"13","key":"10.1016\/j.bcp.2023.115956_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137468","article-title":"Hepatic expression of the Na(+)-taurocholate cotransporting polypeptide is independent from genetic variation","volume":"23","author":"Tremmel","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0255","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jhepr.2019.07.006","article-title":"Mechanistic insights into the inhibition of NTCP by myrcludex B","volume":"1","author":"Donkers","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.bcp.2023.115956_b0260","doi-asserted-by":"crossref","unstructured":"H. Wedemeyer, S. Aleman, M.R. Brunetto, A. Blank, P. Andreone, P. Bogomolov, V. Chulanov, N. Mamonova, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, A. Berger, D. Manuilov, V. Suri, Q. An, B. Da, J. Flaherty, A. Osinusi, Y. Liu, U. Merle, J. Schulze Zur Wiesch, S. Zeuzem, S. Ciesek, M. Cornberg, P. Lampertico, M.Y.R.S. Group, A phase 3, randomized trial of bulevirtide in chronic hepatitis D, N. Engl. J. Med. 389(1) (2023) 22-32.","DOI":"10.1056\/NEJMoa2213429"},{"issue":"6","key":"10.1016\/j.bcp.2023.115956_b0265","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF01189076","article-title":"Endothelial heparan sulphate: compositional analysis and comparison of chains from different proteoglycan populations","volume":"7","author":"Lindblom","year":"1990","journal-title":"Glycoconj. J."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.28013","article-title":"A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses","volume":"63","author":"Verrier","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0275","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/hep.26125","article-title":"A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant","volume":"57","author":"Sureau","year":"2013","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.bcp.2023.115956_b0280","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021378","article-title":"Hepatitis B virus and hepatitis D virus entry, species specificity, and tissue tropism","volume":"5","author":"Watashi","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0285","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0021-9258(17)49936-4","article-title":"The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network","volume":"295","author":"Iwamoto","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2023.115956_b0290","doi-asserted-by":"crossref","first-page":"e13205","DOI":"10.1111\/cmi.13205","article-title":"Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis","volume":"22","author":"Herrscher","year":"2020","journal-title":"Cell. Microbiol."},{"issue":"17","key":"10.1016\/j.bcp.2023.115956_b0295","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1128\/JVI.00873-12","article-title":"Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis","volume":"86","author":"Huang","year":"2012","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0300","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrm.2017.132","article-title":"Mechanisms of clathrin-mediated endocytosis","volume":"19","author":"Kaksonen","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2023.115956_b0305","first-page":"20","article-title":"Inhibitory effect of silibinin on hepatitis B virus entry","volume":"14","author":"Umetsu","year":"2018","journal-title":"Biochem. Biophys. Rep."},{"issue":"Pt 2","key":"10.1016\/j.bcp.2023.115956_b0310","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1242\/jcs.113.2.183","article-title":"Rab GTPases coordinate endocytosis","volume":"113","author":"Somsel Rodman","year":"2000","journal-title":"J. Cell Sci."},{"issue":"11","key":"10.1016\/j.bcp.2023.115956_b0315","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1128\/JVI.00393-13","article-title":"Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment","volume":"87","author":"Macovei","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2023.115956_b0320","doi-asserted-by":"crossref","first-page":"9605252","DOI":"10.1155\/2019\/9605252","article-title":"Stem cell-derived hepatocyte-like cells as model for viral hepatitis research","volume":"2019","author":"Wang","year":"2019","journal-title":"Stem Cells Int."},{"issue":"17","key":"10.1016\/j.bcp.2023.115956_b0325","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.1811064116","article-title":"Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization","volume":"116","author":"Iwamoto","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3803\/EnM.2016.31.1.17","article-title":"Small heterodimer partner and innate immune regulation","volume":"31","author":"Yuk","year":"2016","journal-title":"Endocrinol. Metab. (Seoul)"},{"issue":"5418","key":"10.1016\/j.bcp.2023.115956_b0335","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0340","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0345","doi-asserted-by":"crossref","first-page":"G349","DOI":"10.1152\/ajpgi.00417.2002","article-title":"Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors","volume":"284","author":"Chiang","year":"2003","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"12","key":"10.1016\/j.bcp.2023.115956_b0350","first-page":"1403","article-title":"Farnesoid X receptor: a potential therapeutic target in multiple organs","volume":"35","author":"Zhang","year":"2020","journal-title":"Histol. Histopathol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0355","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0360","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0365","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0370","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.29251","article-title":"Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice","volume":"66","author":"Slijepcevic","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0375","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/86871","article-title":"Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism","volume":"27","author":"Shih","year":"2001","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.bcp.2023.115956_b0380","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0385","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/hep.28882","article-title":"Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay","volume":"65","author":"Zhang","year":"2017","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.bcp.2023.115956_b0390","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1074\/jbc.M010878200","article-title":"Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway","volume":"276","author":"Gupta","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0395","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","article-title":"Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2023.115956_b0400","doi-asserted-by":"crossref","first-page":"20559","DOI":"10.1038\/srep20559","article-title":"Bcl2 is a critical regulator of bile acid homeostasis by dictating Shp and lncRNA H19 function","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0405","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.20090","article-title":"Cellular regulation of hepatic bile acid transport in health and cholestasis","volume":"39","author":"Anwer","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0410","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1210\/me.2005-0159","article-title":"The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism","volume":"20","author":"Eloranta","year":"2006","journal-title":"Mol. Endocrinol."},{"issue":"12","key":"10.1016\/j.bcp.2023.115956_b0415","doi-asserted-by":"crossref","first-page":"8835","DOI":"10.1074\/jbc.275.12.8835","article-title":"Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation","volume":"275","author":"Denson","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166085","article-title":"The role of the retinoid receptor, RAR\/RXR heterodimer, in liver physiology","volume":"1867","author":"Li","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0425","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"issue":"5266","key":"10.1016\/j.bcp.2023.115956_b0430","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.272.5266.1336","article-title":"An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors","volume":"272","author":"Seol","year":"1996","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0435","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1042\/BST20210419","article-title":"Structural insights into glucocorticoid receptor function","volume":"49","author":"Frank","year":"2021","journal-title":"Biochem. Soc. Trans."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0440","doi-asserted-by":"crossref","first-page":"G752","DOI":"10.1152\/ajpgi.00456.2003","article-title":"Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene","volume":"286","author":"Jung","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0445","doi-asserted-by":"crossref","first-page":"G226","DOI":"10.1152\/ajpgi.00012.2008","article-title":"Hepatocyte nuclear factor-4alpha is a central transactivator of the mouse Ntcp gene","volume":"295","author":"Geier","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0450","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/jhep.2003.50100","article-title":"Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression","volume":"37","author":"Jung","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0455","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/MMBR.00043-14","article-title":"Regulation and functions based on complex protein-protein partnerships","volume":"80","author":"Zeke","year":"2016","journal-title":"Microbiol Mol Biol Rev"},{"issue":"35","key":"10.1016\/j.bcp.2023.115956_b0460","doi-asserted-by":"crossref","first-page":"31416","DOI":"10.1074\/jbc.M204818200","article-title":"Interleukin-1 beta-mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependent","volume":"277","author":"Li","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115956_b0465","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.virol.2015.02.026","article-title":"Interleukin 6 inhibits HBV entry through NTCP down regulation","volume":"481","author":"Bouezzedine","year":"2015","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0470","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bbrc.2004.07.102","article-title":"Interleukin-6 regulates hepatic transporters during acute-phase response","volume":"322","author":"Siewert","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0475","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1053\/jhep.2003.50317","article-title":"Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis","volume":"38","author":"Geier","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0480","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/156800805774912999","article-title":"Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells","volume":"5","author":"Wittig","year":"2005","journal-title":"Curr. Drug Targets Immune Endocr. Metabol. Disord."},{"issue":"11","key":"10.1016\/j.bcp.2023.115956_b0485","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1074\/jbc.M116.757567","article-title":"Berberine-induced inactivation of signal transducer and activator of transcription 5 signaling promotes male-specific expression of a bile acid uptake transporter","volume":"292","author":"Bu","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2023.115956_b0490","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1172\/JCI119485","article-title":"Regulation of the rat liver sodium-dependent bile acid cotransporter gene by prolactin. Mediation of transcriptional activation by Stat5","volume":"99","author":"Ganguly","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2023.115956_b0495","doi-asserted-by":"crossref","unstructured":"X. Zhao, W. Iqbal, P. Sun, X. Zhou, Na+-taurocholate co-transporting polypeptide (NTCP) in livers, function, expression regulation, and potential in hepatitis B treatment, 1(4) (2021) 236-249.","DOI":"10.3390\/livers1040019"},{"key":"10.1016\/j.bcp.2023.115956_b0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2016.10.016","article-title":"Protective effects of SRT1720 via the HNF1alpha\/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury","volume":"264","author":"Yu","year":"2016","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0505","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/22221751.2019.1625728","article-title":"Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection","volume":"8","author":"Yan","year":"2019","journal-title":"Emerg Microbes Infect"},{"issue":"1773","key":"10.1016\/j.bcp.2023.115956_b0510","doi-asserted-by":"crossref","first-page":"20180292","DOI":"10.1098\/rstb.2018.0292","article-title":"Phosphodiesterase-induced cAMP degradation restricts hepatitis B virus infection","volume":"374","author":"Evripioti","year":"2019","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0515","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-020-00191-1","article-title":"Complex roles of cAMP-PKA-CREB signaling in cancer","volume":"9","author":"Zhang","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115956_b0520","first-page":"G1165","article-title":"Role of the PI3K\/PKB signaling pathway in cAMP-mediated translocation of rat liver Ntcp","volume":"277","author":"Webster","year":"1999","journal-title":"Am. J. Phys. Anthropol."},{"issue":"38","key":"10.1016\/j.bcp.2023.115956_b0525","doi-asserted-by":"crossref","first-page":"29754","DOI":"10.1074\/jbc.M002831200","article-title":"Cell swelling-induced translocation of rat liver Na(+)\/taurocholate cotransport polypeptide is mediated via the phosphoinositide 3-kinase signaling pathway","volume":"275","author":"Webster","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0530","doi-asserted-by":"crossref","first-page":"G657","DOI":"10.1152\/ajpgi.00529.2011","article-title":"Protein kinase Cdelta differentially regulates cAMP-dependent translocation of NTCP and MRP2 to the plasma membrane","volume":"303","author":"Park","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115956_b0535","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1600-0854.2006.00447.x","article-title":"PKCzeta is required for microtubule-based motility of vesicles containing the ntcp transporter","volume":"7","author":"Sarkar","year":"2006","journal-title":"Traffic"},{"issue":"39","key":"10.1016\/j.bcp.2023.115956_b0540","doi-asserted-by":"crossref","first-page":"33687","DOI":"10.1074\/jbc.M502151200","article-title":"Dephosphorylation of Ser-226 facilitates plasma membrane retention of Ntcp","volume":"280","author":"Anwer","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0545","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00424-013-1367-0","article-title":"Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters","volume":"466","author":"Anwer","year":"2014","journal-title":"Pflugers Arch."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0550","first-page":"G842","article-title":"cAMP increases liver Na+-taurocholate cotransport by translocating transporter to plasma membranes","volume":"273","author":"Mukhopadhayay","year":"1997","journal-title":"Am. J. Phys. Anthropol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0555","doi-asserted-by":"crossref","first-page":"e1009983","DOI":"10.1371\/journal.ppat.1009983","article-title":"The kinesin KIF4 mediates HBV\/HDV entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro","volume":"18","author":"Gad","year":"2022","journal-title":"PLoS Pathog."},{"issue":"10","key":"10.1016\/j.bcp.2023.115956_b0560","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1515\/BC.2005.122","article-title":"Degradation of the sodium taurocholate cotransporting polypeptide (NTCP) by the ubiquitin-proteasome system","volume":"386","author":"Kuhlkamp","year":"2005","journal-title":"Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115956_b0565","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fcimb.2020.00074","article-title":"E-cadherin plays a role in hepatitis B virus entry through affecting glycosylated sodium-taurocholate cotransporting polypeptide distribution","volume":"10","author":"Hu","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0570","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hep.31712","article-title":"Dual agonist of farnesoid X receptor and takeda g protein-coupled receptor 5 inhibits hepatitis B virus infection in vitro and in vivo","volume":"74","author":"Ito","year":"2021","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.bcp.2023.115956_b0575","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1021\/acs.jmedchem.1c00078","article-title":"Design of dimeric bile acid derivatives as potent and selective human NTCP inhibitors","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0580","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","article-title":"Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP","volume":"443","author":"Iwamoto","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0585","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613-1622.2005","article-title":"Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein","volume":"79","author":"Gripon","year":"2005","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0590","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/JVI.01902-09","article-title":"Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction","volume":"84","author":"Schulze","year":"2010","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0595","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115956_b0600","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/jvh.13490","article-title":"Clinical effects of NTCP-inhibitor myrcludex B","volume":"28","author":"Cheng","year":"2021","journal-title":"J. Viral Hepat."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0605","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0610","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.27159","article-title":"Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism","volume":"60","author":"Oehler","year":"2014","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bcp.2023.115956_b0615","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.chembiol.2018.04.011","article-title":"De Novo macrocyclic peptide inhibitors of hepatitis B virus cellular entry","volume":"25","author":"Passioura","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0620","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/mp300453k","article-title":"Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)","volume":"10","author":"Dong","year":"2013","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0625","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"Nkongolo","year":"2014","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.bcp.2023.115956_b0630","doi-asserted-by":"crossref","first-page":"8272","DOI":"10.1021\/acs.jmedchem.1c00211","article-title":"Interplay among conformation, intramolecular hydrogen bonds, and chameleonicity in the membrane permeability and cyclophilin A binding of macrocyclic peptide cyclosporin O derivatives","volume":"64","author":"Lee","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0635","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","article-title":"Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity","volume":"66","author":"Shimura","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2023.115956_b0640","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2014.03.017","article-title":"Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle","volume":"106","author":"Blanchet","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2023.115956_b0645","doi-asserted-by":"crossref","unstructured":"J.M. Donkers, B. Zehnder, G.J.P. van Westen, M.J. Kwakkenbos, I.J. AP, R.P.J. Oude Elferink, U. Beuers, S. Urban, S.F.J. van de Graaf, Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP, Sci. Rep. 7(1) (2017) 15307.","DOI":"10.1038\/s41598-017-15338-0"},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0650","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2014.05.018","article-title":"Kinetics of the bile acid transporter and hepatitis B virus receptor Na+\/taurocholate cotransporting polypeptide (NTCP) in hepatocytes","volume":"61","author":"Konig","year":"2014","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115956_b0655","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3851\/IMP2965","article-title":"The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide","volume":"20","author":"Ko","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bcp.2023.115956_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116862","article-title":"Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation","volume":"68","author":"Lee","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2023.115956_b0665","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1021\/jo991687c","article-title":"Total synthesis of cyclosporin O both in solution and in the solid phase using novel thiazolium-, immonium-, and pyridinium-type coupling reagents: BEMT, BDMP, and BEP","volume":"65","author":"Li","year":"2000","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bcp.2023.115956_b0670","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2015.06.007","article-title":"Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity","volume":"120","author":"Wang","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2023.115956_b0675","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.3389\/fmicb.2019.02638","article-title":"Evans Blue inhibits HBV replication through a dual antiviral mechanism by targeting virus binding and capsid assembly","volume":"10","author":"Xiao","year":"2019","journal-title":"Front. Microbiol."},{"issue":"9057","key":"10.1016\/j.bcp.2023.115956_b0680","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(05)62892-9","article-title":"Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor","volume":"349","author":"Carr","year":"1997","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.bcp.2023.115956_b0685","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJM199906033402215","article-title":"Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient","volume":"340","author":"Velasco","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2023.115956_b0690","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1096\/fj.201500134","article-title":"Reciprocal regulation of farnesoid X receptor alpha activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes","volume":"30","author":"Radreau","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2023.115956_b0695","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/bs.podrm.2020.07.004","article-title":"Irbesartan (a comprehensive profile)","volume":"46","author":"Darwish","year":"2021","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0700","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14779072.6.4.447","article-title":"Ezetimibe: cholesterol lowering and beyond","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2023.115956_b0705","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","article-title":"ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans","volume":"92","author":"Kempf","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.bcp.2023.115956_b0710","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2174\/1568026614666140506120647","article-title":"Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism","volume":"14","author":"Sevrioukova","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"issue":"20","key":"10.1016\/j.bcp.2023.115956_b0715","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2174\/0929867327666201006153202","article-title":"Cyclosporine A: chemistry and toxicity - A review","volume":"28","author":"Patocka","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"13","key":"10.1016\/j.bcp.2023.115956_b0720","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2165\/00003495-200565130-00008","article-title":"Sulfasalazine: a review of its use in the management of rheumatoid arthritis","volume":"65","author":"Plosker","year":"2005","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0725","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1742-1241.2000.tb11914.x","article-title":"Rosiglitazone","volume":"54","author":"Goldstein","year":"2000","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0730","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1203475415574970","article-title":"The rise and fall of oral ketoconazole","volume":"19","author":"Gupta","year":"2015","journal-title":"J. Cutan. Med. Surg."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0735","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0740","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.bbrc.2018.04.187","article-title":"A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction","volume":"501","author":"Saso","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0745","doi-asserted-by":"crossref","first-page":"e0168621","DOI":"10.1128\/jvi.01686-21","article-title":"Establishment of a monoclonal antibody against human NTCP that blocks hepatitis B virus infection","volume":"96","author":"Takemori","year":"2022","journal-title":"J. Virol."},{"issue":"19","key":"10.1016\/j.bcp.2023.115956_b0750","doi-asserted-by":"crossref","first-page":"8866","DOI":"10.1128\/JVI.00901-16","article-title":"Modification of three amino acids in sodium taurocholate cotransporting polypeptide renders mice susceptible to infection with hepatitis D virus in vivo","volume":"90","author":"He","year":"2016","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0755","doi-asserted-by":"crossref","first-page":"19125","DOI":"10.1038\/s41598-021-98243-x","article-title":"Curcumin inhibited hepatitis B viral entry through NTCP binding","volume":"11","author":"Thongsri","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0760","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.120.000308","article-title":"Identification of triterpene acids in poria cocos extract as bile acid uptake transporter inhibitors","volume":"49","author":"Cai","year":"2021","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0765","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1021\/acs.jafc.5b05350","article-title":"Lipidomics biomarkers of diet-induced hyperlipidemia and its treatment with Poria cocos","volume":"64","author":"Miao","year":"2016","journal-title":"J. Agric. Food Chem."},{"issue":"7","key":"10.1016\/j.bcp.2023.115956_b0770","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1055\/s-0030-1270823","article-title":"Chemical constituents and pharmacological properties of Poria cocos","volume":"77","author":"Rios","year":"2011","journal-title":"Planta Med."},{"key":"10.1016\/j.bcp.2023.115956_b0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105184","article-title":"Ergosterol peroxide inhibits HBV infection by inhibiting the binding of the pre-S1 domain of LHBsAg to NTCP","volume":"195","author":"Huang","year":"2021","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2023.115956_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152916","article-title":"The major effective components in Shengmai Formula interact with sodium taurocholate co-transporting polypeptide","volume":"59","author":"Zhan","year":"2019","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0785","doi-asserted-by":"crossref","first-page":"21772","DOI":"10.1038\/s41598-020-78618-2","article-title":"Selective hepatitis B and D virus entry inhibitors from the group of pentacyclic lupane-type betulin-derived triterpenoids","volume":"10","author":"Kirstgen","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0790","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/med.10053","article-title":"Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection","volume":"24","author":"Cichewicz","year":"2004","journal-title":"Med. Res. Rev."},{"issue":"02","key":"10.1016\/j.bcp.2023.115956_b0795","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4236\/pp.2012.32018","article-title":"Biological activity of betulinic acid: A review","volume":"03","author":"Ghaffari Moghaddam","year":"2012","journal-title":"Pharmacol. Pharm."},{"key":"10.1016\/j.bcp.2023.115956_b0800","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2014.09.009","article-title":"(-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes","volume":"111","author":"Huang","year":"2014","journal-title":"Antiviral Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0805","doi-asserted-by":"crossref","DOI":"10.3390\/v14040764","article-title":"Fungal secondary metabolite exophillic acid selectively inhibits the entry of hepatitis B and D viruses","volume":"14","author":"Kobayashi","year":"2022","journal-title":"Viruses"},{"issue":"23","key":"10.1016\/j.bcp.2023.115956_b0810","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1128\/JVI.01855-15","article-title":"A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide","volume":"89","author":"Kaneko","year":"2015","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0815","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbrc.2018.04.199","article-title":"Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide","volume":"501","author":"Nio","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0820","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bmc.2015.01.020","article-title":"Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy","volume":"23","author":"Zhang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0825","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1038\/s41598-018-20987-w","article-title":"Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide","volume":"8","author":"Kaneko","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0830","doi-asserted-by":"crossref","DOI":"10.3390\/v13040666","article-title":"Hepatitis D virus entry inhibitors based on repurposing intestinal bile acid reabsorption inhibitors","volume":"13","author":"Kirstgen","year":"2021","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.bcp.2023.115956_b0835","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.cclet.2020.03.017","article-title":"Discovery of a novel sodium taurocholate cotransporting polypeptide (NTCP) inhibitor: Design, synthesis, and anti-proliferative activities","volume":"31","author":"Xiang","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bcp.2023.115956_b0840","doi-asserted-by":"crossref","first-page":"17047","DOI":"10.1038\/srep17047","article-title":"Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide","volume":"5","author":"Okuyama-Dobashi","year":"2015","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2023.115956_b0845","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1074\/jbc.M114.602540","article-title":"Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression","volume":"290","author":"Tsukuda","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0850","doi-asserted-by":"crossref","DOI":"10.3390\/ph16050678","article-title":"Identifying crude drugs in kampo medicines associated with drug-induced liver injury using the japanese adverse drug event report database: A comprehensive survey","volume":"16","author":"Kimura","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0855","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.joim.2020.01.003","article-title":"Aamar-e-Advia (shelf-lives) of drugs in Unani system of medicine: A conceptual review","volume":"18","author":"Yasmeen","year":"2020","journal-title":"J Integr Med"},{"issue":"6","key":"10.1016\/j.bcp.2023.115956_b0860","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0022-3913(90)90298-Q","article-title":"Effects of crude drugs and berberine hydrochloride on the activities of fungi","volume":"64","author":"Nakamoto","year":"1990","journal-title":"J. Prosthet. Dent."},{"issue":"3","key":"10.1016\/j.bcp.2023.115956_b0865","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J. Nat. Prod."},{"issue":"6","key":"10.1016\/j.bcp.2023.115956_b0870","first-page":"3670","article-title":"Natural products: a continuing source of novel drug leads","volume":"1830","author":"Cragg","year":"2013","journal-title":"BBA"},{"issue":"18","key":"10.1016\/j.bcp.2023.115956_b0875","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1517\/14656566.2013.851668","article-title":"Fasiglifam as a new potential treatment option for patients with type 2 diabetes","volume":"14","author":"Kaku","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"issue":"7","key":"10.1016\/j.bcp.2023.115956_b0880","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/dom.12467","article-title":"Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial","volume":"17","author":"Kaku","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.bcp.2023.115956_b0885","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/dom.12693","article-title":"Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study","volume":"18","author":"Kaku","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.bcp.2023.115956_b0890","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1128\/AAC.01331-16","article-title":"Tyrphostin AG1478 inhibits encephalomyocarditis virus and hepatitis C virus by targeting phosphatidylinositol 4-kinase IIIalpha","volume":"60","author":"Dorobantu","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2023.115956_b0895","article-title":"EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation","volume":"22","author":"Gan","year":"2020","journal-title":"Biochem. Biophys. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2023.115956_b0900","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0905","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/hep.28952","article-title":"A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins","volume":"65","author":"Tsukuda","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115956_b0910","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.antiviral.2016.08.008","article-title":"Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation","volume":"133","author":"Tanaka","year":"2016","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.bcp.2023.115956_b0915","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1172\/JCI73805","article-title":"CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses","volume":"124","author":"Yamamoto","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bcp.2023.115956_b0920","first-page":"4670","article-title":"eIF5A2 is an alternative pathway for cell proliferation in cetuximab-treated epithelial hepatocellular carcinoma","volume":"8","author":"Xue","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"16","key":"10.1016\/j.bcp.2023.115956_b0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115603","article-title":"Junceellolide B, a novel inhibitor of Hepatitis B virus","volume":"28","author":"Li","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2023.115956_b0930","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115956_b0935","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.antiviral.2017.06.005","article-title":"Identification of KX2-391 as an inhibitor of HBV transcription by a recombinant HBV-based screening assay","volume":"144","author":"Harada","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2023.115956_b0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104709","article-title":"Identification and characterization of a novel hepatitis B virus pregenomic RNA encapsidation inhibitor","volume":"175","author":"Jo","year":"2020","journal-title":"Antiviral Res."},{"issue":"11","key":"10.1016\/j.bcp.2023.115956_b0945","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01463-20","article-title":"Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731","volume":"64","author":"Huang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.bcp.2023.115956_b0950","doi-asserted-by":"crossref","first-page":"e0212233","DOI":"10.1371\/journal.pone.0212233","article-title":"Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor","volume":"14","author":"Takeuchi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2023.115956_b0955","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ebiom.2019.10.022","article-title":"Niacin analogue, 6-Aminonicotinamide, a novel inhibitor of hepatitis B virus replication and HBsAg production","volume":"49","author":"Ren","year":"2019","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.bcp.2023.115956_b0960","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.bcp.2023.115956_b0965","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1128\/JVI.77.17.9511-9521.2003","article-title":"Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus","volume":"77","author":"Glebe","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2023.115956_b0970","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26738","article-title":"A potent human neutralizing antibody Fc-dependently reduces established HBV infections","volume":"6","author":"Li","year":"2017","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.bcp.2023.115956_b0975","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0166-3542(95)00916-7","article-title":"In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents","volume":"29","author":"St Clair","year":"1996","journal-title":"Antiviral Res."},{"issue":"21","key":"10.1016\/j.bcp.2023.115956_b0980","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","article-title":"Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase","volume":"83","author":"Furman","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522300549X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522300549X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:21:51Z","timestamp":1762096911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522300549X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":196,"alternative-id":["S000629522300549X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115956","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of sodium taurocholate cotransporting polypeptide (NTCP) in HBV-induced hepatitis: Opportunities for developing novel therapeutics","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115956"}}